Item 8.01 Other Events.

On May 24, 2021, NGM Biopharmaceuticals, Inc. issued a press release announcing topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in 171 patients with biopsy-confirmed non-alcoholic steatohepatitis with stage 2 or 3 liver fibrosis. A copy of the press release titled "NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH" is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits




Exhibit                                  Description

99.1          Press release, dated May 24, 2021, titled "NGM Bio Reports Topline
            Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH."


104         Cover Page Interactive Data File (formatted in Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses